Does intra­operative Marginprobe use reduce re­-excision rates?

Not Applicable

Completed

• Conditions: Breast cancer; Cancer

• Registration Number: ISRCTN10169595
• Lead Sponsor: niversity Hospital of South Manchester

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-03-27
• Study Completion: 2020-12-12
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 467

Inclusion Criteria

1. Women aged 18-90 years with DCIS or Invasive Breast cancer containing DCIS diagnosed histopathologically
2. Histologically diagnosed DCIS or invasive lobular cancer in core biopsy (B5a or B5b). Invasive lobular carcinoma does not require concomitant DCIS.
3. Tumour size 1.5cm - 4cm and undergoing BCS
4. Written informed consent

Exclusion Criteria

1. Unsuitable for BCS on basis of tumour size (>4cm) or stage.
2. Radiotherapy contraindicated.
3. No histopathological evidence of DCIS or invasive lobular cancer.
4. Small invasive cancers (<1.5cm)
5. Multicentric Disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen
6. Bilateral disease (diagnosed cancer in both breasts)
7. Neoadjuvant systemic therapy
8. Previous radiation in the operated breast
9. Implants in the operated breast
10. Pregnancy
11. Lactation
12. Cryo-assisted localisation
13. Patients who are undergoing full cavity excision following removal of the main lumpectomy specimen during initial lumpectomy procedure.

Study & Design

• Study Type: Interventional
• Study Design: Not specified